Weight considerations in pharmacotherapy for type 2 diabetes - Wikidata - awgldk - TriplyDB

Weight considerations in pharmacotherapy for type 2 diabetes

Weight considerations in pharmacotherapy for type 2 diabetes

http://www.wikidata.org/entity/Q34159414

about

Weight considerations in pharmacotherapy for type 2 diabetes

http://www.wikidata.org/entity/Q34159414

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Weight considerations in pharmacotherapy for type 2 diabetes

@ast

Weight considerations in pharmacotherapy for type 2 diabetes

@en

Weight considerations in pharmacotherapy for type 2 diabetes

@nl

type

label

Weight considerations in pharmacotherapy for type 2 diabetes

@ast

Weight considerations in pharmacotherapy for type 2 diabetes

@en

Weight considerations in pharmacotherapy for type 2 diabetes

@nl

prefLabel

Weight considerations in pharmacotherapy for type 2 diabetes

@ast

Weight considerations in pharmacotherapy for type 2 diabetes

@en

Weight considerations in pharmacotherapy for type 2 diabetes

@nl

P1433

Q34159414-286DF96A-DF11-4756-B7EC-7076D7A063BB

P1476

Q34159414-E4E36F21-EA34-47AB-BCA8-8211C08E3DB3

P2093

Q34159414-2A5438FB-D98F-410F-93C5-A7A0FA9B92EC

Q34159414-5F55B3EF-1852-461F-BD11-65FAD23AB73D

P2860

Q34159414-01BE33B2-E02E-4626-87D6-8352E3D82CCD

Q34159414-10E93A35-D985-4E6E-B9AF-D44163A70F2E

Q34159414-15CF9E0F-2250-4C7B-A104-23495D995538

Q34159414-15F2062D-F5CF-419A-A5B3-9350B3038DDC

Q34159414-180673CD-8226-4A51-88CB-C033A7334D80

Q34159414-3189464B-F948-4B6E-A691-767418690816

Q34159414-342C4C12-3A25-4E74-9174-A00C9AE878D6

Q34159414-36744087-7836-4A20-B896-1E01F5627497

Q34159414-3A7409BF-B289-4C5E-A9DC-F3A7BA8F11A1

Q34159414-3F5E5DC9-C68F-4EF2-9134-D7DE2D283906

P304

Q34159414-B9023468-D4C1-4451-A51C-6A9664DF8C82

P31

Q34159414-6B4F150B-0050-42D1-8A85-45C5D6641B00

P356

Q34159414-7AC807EF-D145-44A6-964E-E86A05A59EC9

P478

Q34159414-246BA434-FF8D-4907-8B9F-B38C03971580

P577

Q34159414-8621AE8B-57C8-4CB5-8C22-BE776B2BC4EE

P5875

Q34159414-EFE1E7FE-AF06-4417-8EC6-0F78351E5B40

P698

Q34159414-0C5D28BE-0B98-482D-B901-6B3FDEE828EF

P921

Q34159414-BC48D17F-A1D1-4B7E-BDC3-4C56B2340B10

Q34159414-C63901A1-9CEC-4403-9F2A-58B3B5EF61C1

P932

Q34159414-243A7B09-B078-455A-996A-291D720D50B9

P356

P1433

Journal of Obesity

P1476

Weight considerations in pharmacotherapy for type 2 diabetes

@en

P2093

Sangeeta R Kashyap

http://www.w3.org/2001/XMLSchema#string

Vicky Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Effects of intensive glucose lowering in type 2 diabetes

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

A randomized trial of therapies for type 2 diabetes and coronary artery disease

P304

1190-1201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/984245

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47157553

http://www.w3.org/2001/XMLSchema#string

P698

20885921

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

pharmacotherapy

P932

2946585

http://www.w3.org/2001/XMLSchema#string